Vaccines for Cancer Immunotherapy - 1st Edition - ISBN: 9780128140390

Vaccines for Cancer Immunotherapy

1st Edition

A Comprehensive Evidence-based Review on Current Status and Future Perspectives

Authors: Nima Rezaei Mahsa Keshavarz-Fathi
Paperback ISBN: 9780128140390
Imprint: Academic Press
Published Date: 1st August 2018
Page Count: 162
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Vaccines for Cancer Immunotherapy: A Comprehensive Evidence-based Review on Current Status and Future Perspectives not only provides a reference on cancer treatment for clinicians, but also presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, future perspectives on therapeutic cancer vaccines, and more.

Key Features

  • Introduces the feasible immunotherapeutic vaccines for patients with different cancer types
  • Presents the status of past and current vaccines for cancer treatment
  • Considers the advantages and disadvantages of therapeutic cancer vaccines in comparison to conventional treatments
  • Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
  • Analyzes obstacles in the development of therapeutic cancer vaccines
  • Gives a view on future perspectives towards the application of therapeutic cancer vaccines

Readership

Interdisciplinary: clinicians, scientists and researchers working on applying different modalities for cancer treatment, including biological therapies; immunologists, oncologists, biotechnologists, and other specialists dealing with cancer research and therapy

Table of Contents

  1. Cancer immunology
    1. Innate and adoptive immunity
    2. MHC Class I and ǁ
    3. Tumor microenvironment

  2. General approaches in cancer immunotherapy
    1. Immune cells in cancer immunotherapy
    2. Active vs. Passive Immunotherapy

  3. Vaccines
    1. Definition
    2. Cancer vaccine
      1. Preventive cancer vaccine
      2. Therapeutic cancer vaccine

    3. Vectors
    4. Adjuvants
    5. Delivery system
    6. Route of administration

  4. Tumor antigens
    1. Targeting tumor antigens
    2. Epitope spreading
    3. Tumor associated antigens
      1. Definition
      2. Classification and examples

    4. Tumor specific antigens
      1. Definition
      2. Classification
      3. Neo antigens
      4. Shared antigens
      5. Unique antigens

    5. Glycolipids and Glycoproteins as antigens
    6. mono-epitope versus poly-epitope antigen

  5. The Strategy of Allogeneic and Autologous Cancer Vaccine
  6. Personalized Vaccine
  7. Whole Tumor Antigen Vaccine
    1. Tumor cell lysates
    2. Tumor-derived exosomes
    3. Irradiated gene-modified tumor cell lines
    4. Mechanism of Action
    5. Clinical trials
      1. Immune response
      2. Efficacy
      3. Adverse effects

    6. Advantages and disadvantages

  8. Protein and Peptide vaccines
    1. Mechanism of Action
    2. Clinical trials
      1. Immune response
      2. Efficacy
      3. Adverse effects

    3. Approved Vaccines
    4. Advantages and disadvantages

  9. Dendritic Cell vaccine
    1. Mechanism of Action
    2. Clinical trials
      1. Immune response
      2. Efficacy
      3. Adverse effects

    3. Approved Vaccines
    4. Advantages and disadvantages

  10. Genetic Vaccine
    1. Mechanism of Action
    2. DNA Vaccine
      1. Clinical trials
        1. Immune response
        2. Efficacy
        3. Adverse effects

    3. RNA Vaccine
      1. Clinical trials
        1. Immune response
        2. Efficacy
        3. Adverse effects

    4. Advantages and disadvantages

  11. Candidate cancers for vaccination
  12. The obstacles in development of Therapeutic Cancer Vaccine
    1. Tumor antigens
    2. Stage and progression of disease
    3. Prior treatments
    4. Clinical response versus immune response
    5. Designing clinical trials
    6. Other problems

  13. Combination Therapy
    1. Vaccine combined with other immunotherapeutic modalities
    2. Vaccine combined with other cancer treatments (Surgery /radiotherapy / chemotherapy)

  14. The Future Perspective for Therapeutic Cancer Vaccine
  15. Concluding remarks on Therapeutic Cancer Vaccine
  16. References

Details

No. of pages:
162
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
Paperback ISBN:
9780128140390

About the Author

Nima Rezaei

Nima Rezaei is Associate Professor of Clinical Immunology at Tehran University of Medical Sciences, Associate Dean of International Affairs in the School of Medicine, and Director of the Global Academic Program. He received his PhD in clinical immunology and human genetics from the University of Sheffield in the UK. He edits and writes for leading book series, and is the founder and advisor of two research interest groups, the Network of Immunity in Infection, Malignancy and Autoimmunity (NIMA) and the Cancer Immunology Project (CIP).

Affiliations and Expertise

Associate Professor of Clinical Immunology, Tehran University of Medical Sciences, Associate Dean of International Affairs in the School of Medicine, Tehran

Mahsa Keshavarz-Fathi

Mahsa Keshavarz-Farthi is a medical researcher at the Tehran University of Medical Sciences, and the managing director of Cancer Immunology Project (CIP), undertaking and managing different research project in the field of cancer immunology and immunotherapy. She is working on several research projects on immunotherapeutic modalities for cancer.

Affiliations and Expertise

Medical Researcher, Tehran University of Medical Sciences, Tehran

Ratings and Reviews